What PMV Pharmaceuticals does

PMV Pharmaceuticals is a clinical-stage precision oncology biopharmaceutical company developing orally bioavailable small molecules that structurally correct mutated p53 proteins to restore their wild-type tumor suppressor function. Founded in 2013 by David Mack, Arnold Levine (who discovered p53 in 1979), and Thomas Shenk, the company is headquartered in Princeton, New Jersey and has been publicly traded on NASDAQ under the ticker PMVP since its IPO. The company's lead and wholly-owned asset is rezatapopt (PC14586), a first-in-class selective p53 reactivator that stabilizes the Y220C mutant protein by binding the small crevice created when tyrosine is substituted by cysteine at amino acid 220. PMV is running the Phase 2 PYNNACLE registrational trial in advanced solid tumors harboring the TP53 Y220C mutation, where interim data showed a 34% overall response rate across 103 evaluable patients and a 46% response rate in the ovarian cancer subset. The company has received FDA Fast Track designation for solid tumors with p53 Y220C mutation and Orphan Drug Designation in TP53 Y220C-positive ovarian cancer, and is planning an NDA submission in platinum-resistant/refractory ovarian cancer in Q1 2027.

The pipeline also includes an Investigator-Initiated Trial of rezatapopt combined with azacitidine in relapsed/refractory AML/MDS, and undisclosed discovery-stage programs targeting additional p53 hotspot mutations, signaling a platform-extension strategy beyond the lead asset. PMV's business model is pre-commercial: it generates no product revenue, has no approved drugs, and distributes its investigational therapy solely through clinical trial participation and an expanded access program for patients with life-threatening conditions who have exhausted available options. Revenue will be generated only upon future regulatory approval and commercial launch. The company is funded by a combination of historical venture rounds (most recent disclosed round in August 2020 totaling $70M) and public equity capital, with $112.9M in cash and marketable securities as of December 31, 2025 against a FY2025 net loss of $77.7M, and approximately 90.2% institutional ownership reflecting strong professional investor sponsorship heading into the planned NDA filing.

Name

PMV Pharmaceuticals

Legal name

PMV Pharmaceuticals, Inc.

Website

https://pmvpharma.com

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

PMV Pharmaceuticals is a clinical-stage precision oncology company developing rezatapopt (PC14586), a first-in-class oral small molecule that reactivates the p53 Y220C mutant tumor suppressor, targeting patients with advanced solid tumors and platinum-resistant ovarian cancer.

Ownership category

akta.pro rank

Product category

Precision Oncology Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

akta.pro secondary industries

Lead Optimization & Preclinical Candidate Selection (HLAIALAB), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• P53 targeted oncology
• Precision oncology drugs
• Small molecule therapeutics
• Cancer drug development
• Tumor suppressor reactivation

Headquarters

HQ city

Redwood City

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pre-revenue / Clinical-stage: PMV Pharmaceuticals is a clinical-stage biopharmaceutical company with no commercialized products. The company is focused on developing rezatapopt through clinical trials toward regulatory approval. Revenue will be generated from future drug sales upon FDA approval.

Distribution channels2 records

Marketing channels2 records

Core offering

PMV Pharmaceuticals is a clinical-stage precision oncology company developing orally bioavailable small molecule therapeutics that selectively reactivate mutant p53 tumor suppressor proteins. Its lead product rezatapopt (PC14586) is a first-in-class p53 Y220C reactivator designed to structurally correct the mutant protein and restore wild-type tumor suppressor function in patients with locally advanced or metastatic solid tumors harboring the TP53 Y220C mutation. The pipeline also includes combination regimens and additional p53 hotspot mutation programs in discovery.

Product overview

PMV Pharmaceuticals is a clinical-stage precision oncology company developing small-molecule p53 reactivator therapies. The company's lead product is rezatapopt (PC14586), a first-in-class selective p53 Y220C reactivator currently in Phase 2 registrational trials (PYNNACLE) for advanced solid tumors with tumor-agnostic indication. The pipeline also includes an Investigator Initiated Trial combining rezatapopt with azacitidine for AML/MDS, and additional undisclosed p53 hotspot mutation targets in discovery. PMV takes a unique approach to structurally correcting mutant p53 proteins to restore their wild-type tumor suppressor function.

Differentiator

Problem solved

Functional benefit

Products and services

• rezatapopt (PC14586) First-in-class selective p53 Y220C reactivator small molecule designed to be orally available for the treatment of patients with locally advanced or metastatic solid tumors harboring the TP53 Y220C mutation. The compound stabilizes the mutant p53 protein by binding the crevice created when tyrosine is substituted by cysteine at amino acid 220, restoring wild-type tumor suppressor function.
• rezatapopt and azacitidine combination (Investigator-Initiated Trial) Investigator-Initiated Trial combining rezatapopt with azacitidine for treatment of relapsed/refractory AML/MDS, evaluating rezatapopt in hematologic indications beyond the lead solid tumor program.
• Undisclosed p53 hotspot mutation targets (Discovery Pipeline) Pipeline candidates in discovery targeting additional undisclosed p53 hotspot mutations for treating various solid tumors, extending PMV's structural correction approach beyond the Y220C mutation.

Quantifiable outcome

• 34% overall response rate across 103 evaluable patients in Phase 2 PYNNACLE trial
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Aprea Therapeutics: Direct competitor developing eprenetapopt (APR-246), another small molecule p53 reactivator targeting mutant p53 in cancer. Most directly comparable peer given shared mechanism of action and oncology focus.
• ORIC Pharmaceuticals: Clinical-stage precision oncology company developing small molecule therapies targeting cancer resistance mechanisms. Comparable in stage, size, and small molecule oncology focus; PMV Clinical Advisory Board Chair Richard Heyman co-founded ORIC.
• Kura Oncology: Clinical-stage precision oncology company developing small molecule therapies for genomically-defined cancers. Closely comparable in stage, indication focus, and small molecule approach; Kirsten Flowers (PMV board member) was previously Chief Commercial and Strategy Officer at Kura.
• IDEAYA Biosciences: Clinical-stage precision oncology company developing synthetic lethality and targeted therapies. Comparable in stage, biomarker-driven approach, and small molecule modality; Tim Smith held business development roles at IDEAYA.

Broad incumbents

• Mirati Therapeutics: Developed precision oncology drugs including Krazati (adagrasib) for KRAS G12C-mutant cancers. Acquired by Bristol Myers Squibb in 2024 for ~$4.8B; serves as a benchmark for clinical-stage precision oncology M&A outcomes. Charles Baum (former Mirati CEO/President/Founder) sits on PMV's board.
• Blueprint Medicines: Established precision oncology company developing kinase-targeted therapies (Ayvakit, Gavreto). Comparable as a benchmark for biomarker-driven oncology commercialization and a likely pharma-partner comparable.

Emerging players

• Tango Therapeutics: Clinical-stage oncology company developing synthetic lethality-based therapies, including programs targeting p53-deficient cancers. Compares in cancer genetics focus and target identification approach; partial mechanistic overlap with PMV's p53 restoration strategy.
• Foghorn Therapeutics: Clinical-stage oncology company targeting chromatin regulatory proteins, including programs relevant to p53 biology and tumor suppressor function. Comparable in oncology small molecule approach and emerging-stage profile.
• Relay Therapeutics: Clinical-stage precision oncology company using motion-based drug design to develop small molecule therapies for genomically-defined cancers. Comparable in precision oncology approach, small molecule modality, and clinical stage profile.

Others

• Schrödinger: Computational drug discovery platform company with internal oncology pipeline. Adjacent peer — provides enabling technology for structure-based small molecule design similar to PMV's structural correction approach to mutant p53.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pmv-pharmaceuticals-inc.
• Xx.com/pmvpharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles24 records

Funding overview

Funding rounds5 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PMV Pharmaceuticals